User menu

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial

Bibliographic reference Dhainaut, JF ; Laterre, Pierre-François ; Janes, JM ; Bernard, GR ; Artigas, A ; et. al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial. In: Intensive Care Medicine, Vol. 29, no. 6, p. 894-903 (2003)
Permanent URL
  1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, 10.1097/00003246-199206000-00025
  2. Angus Derek C., Wax Randy S., Epidemiology of sepsis: An update : , 10.1097/00003246-200107001-00035
  3. Angus Derek C., Linde-Zwirble Walter T., Lidicker Jeffrey, Clermont Gilles, Carcillo Joseph, Pinsky Michael R., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care : , 10.1097/00003246-200107000-00002
  4. Alberti Corinne, Brun-Buisson Christian, Burchardi Hilmar, Martin Claudio, Goodman Sergey, Artigas Antonio, Sicignano Alberto, Palazzo Mark, Moreno Rui, Boulmé Ronan, Lepage Eric, Le Gall Jean, Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study, 10.1007/s00134-001-1143-z
  5. Vincent Jean-Louis, The Prevalence of Nosocomial Infection in Intensive Care Units in Europe : Results of the European Prevalence of Infection in Intensive Care (EPIC) Study, 10.1001/jama.1995.03530080055041
  6. Brun-Buisson Christian, Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults : A Multicenter Prospective Study in Intensive Care Units, 10.1001/jama.1995.03530120060042
  7. Davies, A, Green, C, Hutton, J, Chinn, C (2001) Severe sepsis: a European estimate of the burden of disease in ICU. Intensive Care Med 27:S284
  8. Beutler Bruce, Poltorak Alexander, Sepsis and evolution of the innate immune response : , 10.1097/00003246-200107001-00002
  9. Ulevitch Richard J., New therapeutic targets revealed through investigations of innate immunity : , 10.1097/00003246-200107001-00004
  10. Aird William C., Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis : , 10.1097/00003246-200107001-00013
  11. Hack C. Erik, Zeerleder Sacha, The endothelium in sepsis: Source of and a target for inflammation : , 10.1097/00003246-200107001-00011
  12. Joyce David E., Gelbert Larry, Ciaccia Angelina, DeHoff Brad, Grinnell Brian W., Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis, 10.1074/jbc.c100017200
  13. Bauer Philippe R., Microvascular responses to sepsis: clinical significance, 10.1016/s0928-4680(02)00007-x
  14. Esmon Charles T, The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant Pathway, 10.1006/jaut.2000.0400
  15. Bajzar L., Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway, 10.1161/01.atv.20.12.2511
  16. Grinnell Brian W., Joyce David, Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis : , 10.1097/00003246-200107001-00020
  17. Yoshikawa Akira, Kaido Toshimi, Seto Shin-ichi, Katsuura Yasuhiro, Imamura Masayuki, Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats, 10.1016/s0168-8278(00)80128-2
  18. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K (1997) Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197–L202
  19. Taylor F B, Chang A, Esmon C T, D'Angelo A, Vigano-D'Angelo S, Blick K E, Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon., 10.1172/jci112902
  20. Bernard Gordon R., Vincent Jean-Louis, Laterre Pierre-Francois, LaRosa Steven P., Dhainaut Jean-Francois, Lopez-Rodriguez Angel, Steingrub Jay S., Garber Gary E., Helterbrand Jeffrey D., Ely E. Wesley, Fisher Charles J., Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis, 10.1056/nejm200103083441001
  21. Vincent Jean-Louis, Angus Derek C., Artigas Antonio, Kalil Andre, Basson Bruce R., Jamal Hassan H., Johnson Gerald, Bernard Gordon R., Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial* : , 10.1097/01.ccm.0000051515.56179.e1
  22. Ely E. Wesley, Bernard Gordon R., Vincent Jean-Louis, Activated Protein C for Severe Sepsis, 10.1056/nejm200209263471315
  23. Siegel Jay P., Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis, 10.1056/nejmsb021512
  24. Warren H. Shaw, Suffredini Anthony F., Eichacker Peter Q., Munford Robert S., Risks and Benefits of Activated Protein C Treatment for Severe Sepsis, 10.1056/nejmsb020574
  25. Vincent J. -L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., Reinhart C. K., Suter P. M., Thijs L. G., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure : On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix), 10.1007/bf01709751
  26. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Scientific and standardization committee communications: towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Available online at: Accessed January 15:2002
  27. KNAUS WILLIAM A., DRAPER ELIZABETH A., WAGNER DOUGLAS P., ZIMMERMAN JACK E., APACHE II : A severity of disease classification system, 10.1097/00003246-198510000-00009
  28. Breslow NE, Day NE (1980) Statistical methods in cancer research, vol I. IARC, Lyon, pp 5–338
  29. Fourrier Francois, Chopin Claude, Goudemand Jenny, Hendrycx Sylvie, Caron Claudine, Rime Alain, Marey Anne, Lestavel Philippe, Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation, 10.1378/chest.101.3.816
  30. Kidokoro Akio, Iba Toshiaki, Fukunaga Masaki, Yagi Yoshihiro, ALTERATIONS IN COAGULATION AND FIBRINOLYSIS DURING SEPSIS : , 10.1097/00024382-199603000-00010
  31. Gando Satoshi, Nanzaki Satoshi, Sasaki Shigeyuki, Aoi Kenichiro, Kemmotsu Osamu, Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock : , 10.1097/00003246-199812000-00030
  32. Asakura Hidesaku, Ontachi Yasuo, Mizutani Tomoe, Kato Minori, Saito Masanori, Kumabashiri Ichiro, Morishita Eriko, Yamazaki Masahide, Aoshima Keiji, Nakao Shinji, An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation : , 10.1097/00003246-200106000-00015
  33. KNAUS WILLIAM A., DRAPER ELIZABETH A., WAGNER DOUGLAS P., ZIMMERMAN JACK E., Prognosis in Acute Organ-System Failure : , 10.1097/00000658-198512000-00004
  34. Knaus WA, Wagner DP (1989) Multiple systems organ failure: epidemiology and prognosis. Crit Care Clin 5:221–232
  35. SUZUKI Koji, NISHIOKA Junji, KUSUMOTO Hiroshi, HASHIMOTO Senichiro, Mechanism of Inhibition of Activated Protein C by Protein C Inhibitor 1 , 10.1093/oxfordjournals.jbchem.a134583
  36. MACIAS W, DHAINAUT J, YAN S, HELTERBRAND J, SEGER M, JOHNSONIII G, SMALL D, Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis, 10.1067/mcp.2002.128148
  37. Roback Mark G., Stack Anne M., Thompson Claudette, Brugnara Carlo, Schwarz H. Peter, Saladino Richard A., ACTIVATED PROTEIN C CONCENTRATE FOR THE TREATMENT OF MENINGOCOCCAL ENDOTOXIN SHOCK IN RABBITS : , 10.1097/00024382-199802000-00011
  38. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH (1986) Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 68:1218–1223
  39. Begg Colin, Improving the Quality of Reporting of Randomized Controlled Trials : The CONSORT Statement, 10.1001/jama.1996.03540080059030
  40. Collins Rory, MacMahon Stephen, Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials, 10.1016/s0140-6736(00)03651-5
  41. Altman Douglas G., The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration, 10.7326/0003-4819-134-8-200104170-00012
  42. Sleight Peter, 10.1186/cvm-1-1-025